**5. Conclusions**

Graves' Disease is frequent in women of reproductive age and in pregnancy. It can lead to maternal, fetal and neonatal complications with potential long-term sequels. For those with known GD before pregnancy a preconception plan should be made to ensure optimal timing for pregnancy when GD is well under control. Management options for GD and their implications to pregnancy should be discussed. TRAbs are the pathogenic hallmark of GD and they can cause harm to the fetus and the neonate by crossing the placenta. Antithyroid drugs are traditionally used to treat GD, however in pregnancy they can be teratogenic and they can induce fetal and neonatal hypothyroidism by placental passage. Fetal ultrasound during pregnancy is helpful for fetal assessment and for diagnosing fetal goiter. The type of fetal thyroid disfunction when goiter is associated can be usually deduced by assessing the maternal state. Fetal treatment is in most cases achieved by treating the mother – increasing or decreasing ATDs. Neonatal assessment in newborns of mothers with known GD is recommended. Maternal GD, like other autoimmune conditions can flare in the postpartum, therefore, the mother should also be under supervision. Breastfeeding is allowed in women on regular doses of ATDs.
